Lu Junjun, Li He, Guo Peng, Shen Rui, Luo Yingbin, Ge Qiao, Shi Wenfei, Li Yan, Zhu Weikang
Department of Tumor, Shanghai Municipal Hospital of Traditional Chinese Medicine.
Department of Traditional Chinese Medicine, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital.
Onco Targets Ther. 2017 Nov 13;10:5429-5437. doi: 10.2147/OTT.S149197. eCollection 2017.
To evaluate the effect of polymorphism (C 100C>T, rs1065852) on clinical outcomes of female Asian breast cancer patients with tamoxifen adjuvant treatment.
Meta-analysis of retrospective cohort studies published in July 2017 was performed. Fifteen studies with 1,794 Asian breast cancer patients were included, using strict eligibility requirements. Associations of disease-free survival (DFS), overall survival (OS) and recurrence rate after tamoxifen intake, with polymorphism were investigated through random effects models.
polymorphism was found to have effect on DFS and recurrence rate in various comparison models, but not on overall survival in the female Asian breast cancer patients.
In conclusion, our meta-analysis suggests that significant association of / () genotype with poorer DFS and recurrence exists in female Asian breast cancer patients with tamoxifen 20 mg/day adjuvant treatment. In the future, large and well-designed studies are required to illustrate the interactions of genetic variants, including polymorphism and tamoxifen response on female breast cancer patients.
评估多态性（C100C>T，rs1065852）对接受他莫昔芬辅助治疗的亚洲女性乳腺癌患者临床结局的影响。
对2017年7月发表的回顾性队列研究进行荟萃分析。纳入15项研究，共1794例亚洲乳腺癌患者，采用严格的纳入标准。通过随机效应模型研究他莫昔芬治疗后无病生存期（DFS）、总生存期（OS）和复发率与多态性的关联。
在各种比较模型中，发现多态性对亚洲女性乳腺癌患者的DFS和复发率有影响，但对总生存期无影响。
总之，我们的荟萃分析表明，在接受20mg/天他莫昔芬辅助治疗的亚洲女性乳腺癌患者中，/（）基因型与较差的DFS和复发存在显著关联。未来，需要开展大规模、设计良好的研究来说明基因变异之间的相互作用，包括多态性与他莫昔芬对女性乳腺癌患者反应之间的相互作用。
